Pinpointing who will and won’t get Alzheimer’s disease is tricky for doctors, but new research suggests it may soon get ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Recent research highlights carnosic acid, found in rosemary and sage, as a potential weapon against Alzheimer's. Scientists ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

US FDA approves expanded label for GE HealthCare’s Vizamyl PET imaging agent for beta amyloid detection: Arlington Heights, Illinois Thursday, June 26, 2025, 13:00 Hrs [IST] GE ...

The memories and autonomy destroyed by Alzheimer’s disease continue to make it one of the greatest health challenges faced by ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

A study revealed carnosic acid in herbs may help combat Alzheimer's by reducing inflammation and improving brain cell ...